Skip to content
Screener

CRISPR Therapeutics CRSP Other income, net (Note 6)

Other income, net (Note 6) at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$6.13M-29.9%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$212K+130%
Sana Biotechnology logo
Sana BiotechnologySANA
$453K+81.9%
Prime Medicine logo
Prime MedicinePRME
$55K+206%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$214K+3.4%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$4.99B-2.6%
Enterprise value$5.36B+4.1%
P/S1,217×+1,082×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:48 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204188
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Total operating expenses131,706149,289
Loss from operations(130,248)(148,424)
Other income:
Other income, net8,15613,537
Total other income, net8,15613,537
Net loss before income taxes(122,092)(134,887)
Provision for income taxes(839)(1,109)
Net loss(122,931)(135,996)

Item 1. Financial Statements

FAQ

What is CRISPR Therapeutics's other income, net (note 6)?
CRISPR Therapeutics (CRSP) reported other income, net (note 6) of $8.16M in Q1 2026.
How has CRISPR Therapeutics's other income, net (note 6) changed year-over-year?
CRISPR Therapeutics's other income, net (note 6) decreased by 39.8% year-over-year, from $13.54M to $8.16M.
What is the long-term trend for CRISPR Therapeutics's other income, net (note 6)?
Over 4 years (2021 to 2025), CRISPR Therapeutics's other income, net (note 6) has grown at a 94.9% compound annual growth rate (CAGR), from $6M to $86.61M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about CRISPR Therapeutics's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude